Immix Biopharma Inc expected to post a loss of 21 cents a share - Earnings Preview

Immix Biopharma

09/08/2024 23:56

* Immix Biopharma Inc  IMMX.OQ   IMMX.O  is expected to show
no
change in quarterly revenue when it reports  results on August
11 (estimated) for the period ending June 30 2024
    * 
    * ​LSEG's mean analyst estimate for Immix Biopharma Inc is
for a
loss of 21 cents per share. 
    * The one available analyst rating on the shares is "buy".  
    * The average consensus recommendation for
the pharmaceuticals
peer group is also "Buy".​
    * Wall Street's median 12-month price target for Immix
Biopharma
Inc is $7.00​, above​ its last closing price of $1.95. ​​​

This summary was machine generated August 9 at 22:56 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)